Solvay Pharma`s arm gets USFDA nod for CREON capsules
Solvay Pharma India announced that its US unit Solvay Pharmaceuticals has obtained a final approval from US Food and Drug Administration (USFDA) to market CREON capsules on prescription basis.
The said drug would be in the strength of 2000 units for 120 ml of the formula. It would be used for the treatment of exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF) or other conditions.
Exocrine Pancreatic Insufficiency (EPI) is a condition resulting from a deficiency in the production and/or secretion of pancreatic enzymes that are necessary to digest nutrients in food.
May 14, 2009